Mast Therapeutics (MSTX) Announces Vepoloxamer Data Selected For Presentation at ASH Meeting

November 16, 2015 8:07 AM EST Send to a Friend
Mast Therapeutics (NYSE: MSTX) today announced that data from nonclinical studies investigating vepoloxamer, its lead product candidate, will be featured ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login